Canakinumab Tapering in Still's Disease
You can reduce – but not stop – canakinumab therapy in patients who are…
View Resource
Tocilizumab May Benefit COVID-19 Pneumonia
A retrospective, observational study published in Lancet Rheumatology has shown that tocilizumab (TCZ) may reduce…
View Resource
Canakinumab First FDA-Approved Therapy for Adult-Onset Still's Disease
Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still’s disease (AOSD), the…
View Resource
TNR Grand Rounds – Cytokine Storm Syndromes
This week’s Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama –…
View Resource
High Dose Anakinra Effective in COVID-19
Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers…
View Resource
Earlier Anakinra Initiation Warranted in Still's Disease
An Italian study examined the outcomes in adult onset Still’s disease (AOSD) based on…
View Resource
Methotrexate and the Risk of Lung Disease
Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related…
View Resource
Tofacitinib Effective in Refractory Still's Disease
Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in…
View Resource
Systemic JIA-Associated Lung Disease
A disease you’ve never heard of is becoming increasingly common and carries a very…
View Resource
Autoinflammatory Diseases at the ACR Annual Meeting
It has been a wonderful year for autoinflammatory diseases at the ACR Annual Meeting.…
View Resource